Inflammatory biomarkers, hormone replacement therapy, and incident coronary heart disease: prospective analysis from...

Area of Science:

• Cardiovascular Disease Epidemiology
• Biomarkers of Inflammation
• Postmenopausal Health

Background:

• Hormone replacement therapy (HRT) is known to increase C-reactive protein (CRP) levels.
• Elevated CRP and other inflammatory biomarkers are linked to increased cardiovascular risk.
• The clinical significance of HRT's effect on CRP and its relation to vascular risk remains unclear.

Purpose of the Study:

• To evaluate the association between baseline CRP and interleukin 6 (IL-6) levels and the incidence of coronary heart disease (CHD).
• To investigate the relationship between HRT use, CRP, and IL-6 levels concerning subsequent vascular risk.

Main Methods:

• A prospective, nested case-control study within the Women's Health Initiative.
• Matched 304 postmenopausal women with incident CHD to 304 event-free controls.
• Analyzed baseline CRP and IL-6 levels, HRT use, and CHD incidence.

Main Results:

• Higher median baseline CRP and IL-6 levels were observed in CHD cases versus controls.
• Elevated CRP and IL-6 were significantly associated with increased odds of incident CHD.
• HRT use was linked to higher CRP but not IL-6; baseline inflammatory marker levels were stronger CHD predictors than HRT status.

Conclusions:

• CRP and IL-6 are independent predictors of vascular events in postmenopausal women.
• HRT elevates CRP levels, but baseline CRP and IL-6 are more significant predictors of cardiovascular risk than HRT use.
• Inflammatory biomarkers play a crucial role in assessing vascular risk in postmenopausal women.